Over the last few months, IDF has fielded hundreds of calls and e-mails about challenges individuals with PI are facing in accessing immunoglobulin (Ig) products. On August 12, the Food and Drug Administration (FDA) addressed the product shortage, and how it could impact patient care.
The supply of donated plasma and the products produced from it, like Ig, are low while the demand continues to rise. Unfortunately, there are no quick or easy fixes. We’re doing what we can to seek solutions by gathering information from thought leaders from the FDA and members of the plasma supply chain.
If you’re experiencing Ig access issues and you haven’t yet reached out to us, please let us know through www.primaryimmune.org/ask-idf. Also, even if you haven’t experienced access issues, login or create an account and make sure you’re subscribed to all of our mailing lists.
It’s imperative that we know exactly what the community is experiencing and hearing, and it’s equally imperative that we’re able to reach you as the latest information becomes available to us.
This article originally appeared in the IDF monthly e-newsletter, Primary Immune Tribune. Click here to subscribe.